Conference Coverage
Conference Coverage
Consider phototherapy for certain psoriasis patients
Conference Coverage
Oral tofacitinib scores against psoriasis in phase III trial
Key clinical point: Multiple measures of quality of life and disease burden improved similarly in psoriasis patients regardless of whether they...
Conference Coverage
Secukinumab tames psoriatic arthritis in FUTURE 2 trial
Key clinical point: Secukinumab could prove to be a major new therapy for psoriatic arthritis. Major finding: After 24 weeks, a response of at...
Conference Coverage
Few psoriatic arthritis patients achieve minimal disease activity on methotrexate
Key clinical point: It may be time to rethink methotrexate’s role as first-line therapy for psoriatic arthritis. Major finding: Only 17.4% of...
Conference Coverage
Psoriasis is independently associated with advanced liver fibrosis
Key clinical point: Noninvasive screening for advanced hepatic fibrosis may be in order for older patients with mild psoriasis never treated...
Conference Coverage
Certolizumab achieves sustained skin improvement in psoriatic arthritis
Key clinical point: Certolizumab pegol maintains sustained improvement in the dermatologic manifestations of psoriatic arthritis through 96 weeks...
Conference Coverage
Apremilast succeeds against nail, scalp, palmoplantar psoriasis
Key clinical point: Apremilast significantly improved psoriasis in a subset of patient with nail, scalp, and palmoplantar involvement. Major...
Conference Coverage
VIDEO: Don’t discount topical therapy for psoriasis
Conference Coverage
Novel psoriasis biologic wows with jaw-dropping results
Key clinical point: Up to 66 months after receiving a single subcutaneous injection of a biologic agent that selectively blocks interleukin-23,...
Conference Coverage
Psoriasiform lesions linked to anti-TNF treatment
Key clinical point: Inflammatory bowel disease patients on anti–tumor necrosis factor treatment often develop psoriasiform skin lesions. Major...